Is hepatotoxicity in patients treated with gemtuzumabozogamicin due to specific targeting of hepatocytes?

Leuk Res. 2011 Jun;35(6):e84-6. doi: 10.1016/j.leukres.2011.01.025. Epub 2011 Feb 16.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Aminoglycosides / adverse effects*
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antigens, CD / metabolism*
  • Antigens, Differentiation, Myelomonocytic / metabolism*
  • Antineoplastic Agents / adverse effects
  • Chemical and Drug Induced Liver Injury / etiology*
  • Chemical and Drug Induced Liver Injury / metabolism
  • Gemtuzumab
  • Hepatocytes / drug effects*
  • Hepatocytes / metabolism
  • Humans
  • Immunohistochemistry
  • Leukemia, Myeloid / drug therapy
  • Sialic Acid Binding Ig-like Lectin 3

Substances

  • Aminoglycosides
  • Antibodies, Monoclonal, Humanized
  • Antigens, CD
  • Antigens, Differentiation, Myelomonocytic
  • Antineoplastic Agents
  • CD33 protein, human
  • Sialic Acid Binding Ig-like Lectin 3
  • Gemtuzumab